News
- Author:
- Andrew D. Bowser
Publish date: June 28, 2019
MILAN – For high-risk cases, CCPDMA has superior outcomes, compared with standard excision, according to results of the meta-analysis.
News
- Author:
- Andrew D. Bowser
Publish date: June 28, 2019
MILAN – Recruitment of patients in phase 3 studies of ruxolitinib cream for AD has just started.
News
- Author:
- Andrew D. Bowser
Publish date: June 27, 2019
MILAN – While not yet approved, science, data, and treatment algorithms are lining up in a positive direction.
News
- Author:
- Andrew D. Bowser
Publish date: June 27, 2019
MILAN – There was an “imbalance” in the types of medications prescribed for older and younger patients in the registry, with biologics used more fr...
News
- Author:
- Andrew D. Bowser
Publish date: June 27, 2019
MILAN – Improvements in pruritus occurred early with upadacitinib and were pronounced at the highest dose studied, 30 mg daily.
News
- Author:
- Andrew D. Bowser
Publish date: June 26, 2019
MILAN – It’s not clear why patients receiving cancer immunotherapy treatment develop bullous pemphigoid.
News
- Author:
- Andrew D. Bowser
Publish date: June 25, 2019
MILAN – A monoclonal antibody directed against DC-HIL reduced melanoma growth and metastasis in animal models.
News
- Author:
- Andrew D. Bowser
Publish date: June 21, 2019
MILAN – In a small retrospective study, 85% of patients treated with the oral antimalarial agent had marked improvement or full remission.
News
- Author:
- Andrew D. Bowser
Publish date: June 21, 2019
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
News
- Author:
- Andrew D. Bowser
Publish date: June 14, 2019
MILAN – Toxicities occurred early in treatment, and having both increased risk of adverse events in other organ systems.
News
- Author:
- Andrew D. Bowser
Publish date: June 13, 2019
MILAN – Combining pembrolizumab with vismodegib was not clearly superior to pembrolizumab alone in a proof-of-concept study.
News
- Author:
- Andrew D. Bowser
Publish date: June 11, 2019
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.
News
- Author:
- Andrew D. Bowser
Publish date: June 7, 2019
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib.<...
News
- Author:
- Andrew D. Bowser
Publish date: June 7, 2019
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
News
- Author:
- Andrew D. Bowser
Publish date: June 6, 2019
Pivotal phase 2 portion of study to commence later this year.
